PT1278750E - Derivados de imidazopirimidina e derivados de triazolopirimidina - Google Patents

Derivados de imidazopirimidina e derivados de triazolopirimidina

Info

Publication number
PT1278750E
PT1278750E PT01936242T PT01936242T PT1278750E PT 1278750 E PT1278750 E PT 1278750E PT 01936242 T PT01936242 T PT 01936242T PT 01936242 T PT01936242 T PT 01936242T PT 1278750 E PT1278750 E PT 1278750E
Authority
PT
Portugal
Prior art keywords
sup
sub
derivatives
optionally substituted
imidazopyrimidine
Prior art date
Application number
PT01936242T
Other languages
English (en)
Inventor
Takeshio Yura
Arnel B Concepcion
Gyoonhee Han
Makiko Hiraoka
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy B Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Ming Wang
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PT1278750E publication Critical patent/PT1278750E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT01936242T 2000-04-28 2001-04-17 Derivados de imidazopirimidina e derivados de triazolopirimidina PT1278750E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体

Publications (1)

Publication Number Publication Date
PT1278750E true PT1278750E (pt) 2004-11-30

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01936242T PT1278750E (pt) 2000-04-28 2001-04-17 Derivados de imidazopirimidina e derivados de triazolopirimidina

Country Status (38)

Country Link
US (1) US6911443B2 (pt)
EP (1) EP1278750B1 (pt)
JP (2) JP2001302667A (pt)
KR (1) KR20030009456A (pt)
CN (1) CN1263756C (pt)
AR (1) AR033367A1 (pt)
AT (1) ATE272639T1 (pt)
AU (1) AU783043B2 (pt)
BG (1) BG107166A (pt)
BR (1) BR0110404A (pt)
CA (1) CA2407531A1 (pt)
CZ (1) CZ20023551A3 (pt)
DE (1) DE60104671T2 (pt)
DK (1) DK1278750T3 (pt)
DO (1) DOP2001000151A (pt)
EE (1) EE200200606A (pt)
ES (1) ES2225546T3 (pt)
HK (1) HK1058362A1 (pt)
HR (1) HRP20020943A2 (pt)
HU (1) HUP0300846A2 (pt)
IL (1) IL151919A0 (pt)
MA (1) MA25746A1 (pt)
MX (1) MXPA02010579A (pt)
MY (1) MY141578A (pt)
NO (1) NO20025154D0 (pt)
NZ (2) NZ526221A (pt)
PE (1) PE20011287A1 (pt)
PL (1) PL358106A1 (pt)
PT (1) PT1278750E (pt)
RU (1) RU2306313C2 (pt)
SI (1) SI1278750T1 (pt)
SK (1) SK15332002A3 (pt)
SV (1) SV2001000416A (pt)
TR (1) TR200402300T4 (pt)
TW (1) TWI222974B (pt)
UA (1) UA72615C2 (pt)
WO (1) WO2001083485A1 (pt)
ZA (1) ZA200207676B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
EP1674454A4 (en) * 2003-10-17 2006-12-27 Nippon Kayaku Kk SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO 1,5-A-PYRIMIDINE DERIVATIVE AND THE USE THEREOF
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
SI1718649T1 (sl) 2004-01-31 2009-10-31 Actimis Pharmaceuticals Inc Derivati imidazo 1,2-c pirimidinilocetne kisline
MXPA06014637A (es) * 2004-06-25 2007-02-12 Amgen Inc Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA200800664A1 (ru) * 2005-10-13 2009-02-27 Глаксо Груп Лимитед Производные пирролопиримидина в качестве ингибиторов syk
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
PL2099447T3 (pl) * 2006-11-22 2013-06-28 Incyte Holdings Corp Imidazotriazyny i imidazopirmidyny jako inhibitory kinaz
CN101611035A (zh) 2006-12-28 2009-12-23 大正制药株式会社 吡唑并嘧啶化合物
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
PT2205569E (pt) 2007-09-25 2012-05-25 Actimis Pharmaceuticals Inc Alquiltiopirimidinas como antagonistas de crth2
MX2010003178A (es) 2007-09-25 2010-04-30 Actimis Pharmaceuticals Inc Primidinas sustituidas con 2-s-bencilo como antagonistas de crth2.
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
CN104744476B (zh) * 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并吡嗪syk抑制剂
CN104059073B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并哌嗪syk抑制剂
EP2443123B1 (en) * 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
GEP20156243B (en) 2009-12-23 2015-02-10 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
SG184870A1 (en) * 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
AU2012253885A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
ES2661444T3 (es) * 2011-12-28 2018-04-02 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
US9487504B2 (en) 2012-06-20 2016-11-08 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
WO2014100314A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
EP2988749B1 (en) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
SI3027171T1 (sl) 2013-07-30 2020-08-31 Gilead Connecticut, Inc. Formulacija inhibitorjev SYK
ES2822285T3 (es) 2013-07-30 2021-04-30 Kronos Bio Inc Polimorfo de inhibidores de SYK
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
PT3119772T (pt) * 2014-03-19 2019-09-05 Boehringer Ingelheim Int Inibidores de syk heteroarilo
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
PL3347353T3 (pl) 2015-09-11 2020-01-31 Boehringer Ingelheim International Gmbh Heteroaryle podstawione pirazolilem i ich zastosowanie jako leki
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
JP2020537678A (ja) 2017-10-19 2020-12-24 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用
CN111936136A (zh) 2017-11-14 2020-11-13 儿童医学中心公司 新咪唑并嘧啶化合物及其用途
KR20200088398A (ko) 2017-11-14 2020-07-22 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2019235570A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 グリオーマの処置剤および医薬組成物
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
LT3873903T (lt) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
EP1017682A4 (en) * 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
NZ526221A (en) 2005-01-28
DOP2001000151A (es) 2002-05-15
TWI222974B (en) 2004-11-01
US20040054179A1 (en) 2004-03-18
US6911443B2 (en) 2005-06-28
JP2001302667A (ja) 2001-10-31
JP2003535067A (ja) 2003-11-25
MA25746A1 (fr) 2003-04-01
NO20025154L (no) 2002-10-25
AU783043B2 (en) 2005-09-22
SK15332002A3 (sk) 2003-06-03
NO20025154D0 (no) 2002-10-25
IL151919A0 (en) 2003-04-10
EP1278750B1 (en) 2004-08-04
DE60104671D1 (de) 2004-09-09
SI1278750T1 (en) 2005-02-28
ZA200207676B (en) 2003-09-25
NZ522241A (en) 2004-04-30
ES2225546T3 (es) 2005-03-16
BG107166A (bg) 2003-06-30
EE200200606A (et) 2004-04-15
EP1278750A1 (en) 2003-01-29
CN1439009A (zh) 2003-08-27
MY141578A (en) 2010-05-14
UA72615C2 (en) 2005-03-15
CA2407531A1 (en) 2001-10-25
SV2001000416A (es) 2001-07-03
DE60104671T2 (de) 2005-12-29
MXPA02010579A (es) 2003-05-14
BR0110404A (pt) 2003-02-11
HRP20020943A2 (en) 2005-02-28
WO2001083485A1 (en) 2001-11-08
PL358106A1 (en) 2004-08-09
AR033367A1 (es) 2003-12-17
ATE272639T1 (de) 2004-08-15
KR20030009456A (ko) 2003-01-29
CN1263756C (zh) 2006-07-12
RU2306313C2 (ru) 2007-09-20
HK1058362A1 (en) 2004-05-14
DK1278750T3 (da) 2004-11-22
TR200402300T4 (tr) 2004-12-21
HUP0300846A2 (hu) 2003-08-28
AU6220401A (en) 2001-11-12
CZ20023551A3 (cs) 2003-01-15
PE20011287A1 (es) 2002-02-27

Similar Documents

Publication Publication Date Title
PT1278750E (pt) Derivados de imidazopirimidina e derivados de triazolopirimidina
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
ATE301640T1 (de) Anellierte 4-carboxyamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp-hemmer
BR9710780A (pt) Novos compostos de para-terefenila
IE883391L (en) Novel compounds
KR860004894A (ko) 벤조옥사졸- 및 벤조티아졸아민 유도체의 제조방법
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200100983A1 (ru) Производные 13-метилэритромицина
NO911121D0 (no) Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
YU48791A (sh) Biciklični ketali i postupak za njihovu izradu
AU6124699A (en) Aromatic amine derivatives, process for the preparation thereof and agents containing the same
DE60001182T2 (de) Erythromycin-Derivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
FI832739A (fi) 5-alkyl-1,6-naftyridin-2(1h)-oner, mellanprodukter deras framstaellning och anvaendning som hjaertlaekemedel
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
HUT41739A (en) Herbicidal and plant growth regulating compositions comprising novel "1-aryl-5-alkoxy-imino-alkyl-aminopyrazoles as active substance and process for preparing the novel active substances
AR035076A1 (es) Procedimiento y derivados ester utiles para la preparacion de cefalosporinas
DE60111651D1 (de) Verfahren zur herstellung von substanz gm-95
AU1001897A (en) Process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer
ATE231858T1 (de) Verfahren zur herstellung von 3-substituierten 4- phenyl-piperidin derivaten
DK0703237T3 (da) Fremgangsmåde til fremstilling af thio-phospholipider af ether-typen
AU2155388A (en) Chemical compounds
ATE8633T1 (de) Vinyl-3-cephalosporinverbindungen und ihre herstellung.
HUP0301500A2 (hu) Eljárás imidazo [1,2-c][2,3]benzodiazepin-származékok és köztitermékeik előállítására
FR2751655B1 (fr) Nouveaux derives de bis-imides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0521766T3 (da) Hidtil ukendt fremgangsmåde til syntese af enantiomerer af 3-aminochromanderivater